Spineology Clinical Outcomes Trial: An IDE Investigation

NCT ID: NCT02347410

Last Updated: 2021-10-20

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

102 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-22

Study Completion Date

2020-03-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluated the safety and effectiveness of the Spineology Interbody Fusion System (SIFS) in an instrumented interbody lumbar fusion in subjects presenting with symptomatic single-level lumbar degenerative disc disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This regulated prospective, multi-center, Institutional Review Board (IRB) approved single-arm performance goal clinical investigation was conducted at 10 centers with 102 subjects being enrolled and treated.

Subjects were actively evaluated from pre-op to 24-months postoperative. Based on enrollment duration, some subjects were remotely assessed through self-administered surveys at 36- and/or 48-months.

The primary endpoint, assessed at 24-months postoperative, is a composite score that includes pain, function, fusion and safety assessments.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lumbar Degenerative Disc Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Investigation Group

This is a single-arm investigation. All subjects were treated with the SIFS device filled with bone graft. Posterior fixation required.

Group Type OTHER

SIFS graft containment device

Intervention Type DEVICE

The SIFS mesh is a graft containment and reinforcement device. Following conventional thorough discectomy, the disc space is entered through a small portal in the annulus, the SIFS mesh is introduced, deployed and then filled with bone graft. Bilateral commercially available posterior lumbar fixation is applied.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SIFS graft containment device

The SIFS mesh is a graft containment and reinforcement device. Following conventional thorough discectomy, the disc space is entered through a small portal in the annulus, the SIFS mesh is introduced, deployed and then filled with bone graft. Bilateral commercially available posterior lumbar fixation is applied.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SIFS mesh

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Skeletally mature;
* Confirmed symptomatic single-level lumbar degenerative disc disease (DDD) between L2 and S1;
* Minimum low back Visual Analog Scale (VAS) pain score of 40mm;
* Minimum Oswestry Disability Index (ODI) score of 40;
* Received at least 6-months of conservative care; and
* Willing and able to comply with protocol evaluations and provide informed consent.

Exclusion Criteria

* Previous fusion or total disc replacement at the index level;
* Greater than Grade I spondylolisthesis;
* Has symptomatic multi-level lumbar DDD;
* Active systemic infection or infection at the local surgical site;
* Active or suspected malignancy;
* Body Mass Index of greater than or equal to 40;
* Significant metabolic bone disease;
* Taking medication known to interfere with bone healing;
* Has a current substance abuse disorder;
* Has a somatoform, dissociative, eating or psychotic disorder;
* Waddell Signs of inorganic behavior;
* Current tobacco user;
* Is a prisoner;
* If female, pregnant or contemplating pregnancy during follow-up period; or
* Enrolled in a concurrent clinical investigation that may confound the findings of the current investigation
Minimum Eligible Age

21 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Spineology, Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Donald Erickson, M.D.

Role: STUDY_CHAIR

Retired

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Florida Orthopaedic Associates

DeLand, Florida, United States

Site Status

Spine Institute of Louisiana

Shreveport, Louisiana, United States

Site Status

Thibodaux Regional Medical Center

Thibodaux, Louisiana, United States

Site Status

Georgetown University Hospital

Clinton, Maryland, United States

Site Status

Brigham & Women's Hospital

Boston, Massachusetts, United States

Site Status

Sports Medicine North

Peabody, Massachusetts, United States

Site Status

Bronson Healthcare Methodist Hospital - Neuroscience Center

Kalamazoo, Michigan, United States

Site Status

Mayo Clinic Hospital - College of Medicine

Rochester, Minnesota, United States

Site Status

University at Buffalo/SUNY

Buffalo, New York, United States

Site Status

University of Vermont Medical Center

South Burlington, Vermont, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

62-180

Identifier Type: -

Identifier Source: org_study_id